Fundraising Fox
/Companies
Sign in

WhiteLab Genomics

YC W22

Paris, FR · Founded 2019 · 40 employees · 5 known investors

Find your way into WhiteLab Genomics

Sign up to see every warm intro you have to WhiteLab Genomics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the WhiteLab Genomics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

WhiteLab Genomics uses AI and computational methods to analyze biological data and accelerate genomic drug discovery and development. The company serves pharmaceutical and biotech organizations seeking to reduce timelines and de-risk the development of genomic medicines.

AI & Machine LearningBiotechDeep TechHealthtechArtificial IntelligenceGene TherapyCell TherapyGenomicsFranceUnited States of AmericaEuropeAmerica / CanadaPartly Remote

Founders & leadership· Y Combinator alumni (W22)

WhiteLab Genomics was founded in 2019 by David Delbourgo and Julien Cottineau.

DDDavid Delbourgo
David DelbourgoCEO co-founderDavid Delbourgo has over two decades of healthcare industry experience across business development, marketing, and commercial operations roles, including time at GE Healthcare. He holds an MBA from Chicago Booth and a master's degree in biomedical engineering from the University of Compiègne.
JCJulien Cottineau
Julien CottineauCo-founder · Chief Scientific Officer CSOJulien Cottineau held a senior application scientist position at Genomic Vision and completed postdoctoral research on human immune deficiencies at Rockefeller University and Necker Hospital. He earned a PhD in genetics, molecular biology, and immunology from Université Pierre & Marie Curie.
MT
Maud ThouverezHead of People \u0026 Culture
NL
Nathan LeeHead of Partnerships
NL
Natasha LiuTalent Acquisiton and Empoyer Brand Managerformer

Investors · 5

Atlantic Vantage PointreportedParis · $1M – $150M

How we know: Y Combinator's founder network · Not right? Tell us

Debiopharm Innovation FundreportedLausanne · $1M – $5M

How we know: Y Combinator's founder network · Not right? Tell us

Omnes CapitalreportedParis

How we know: Y Combinator's founder network · Not right? Tell us

Also in the syndicate · 1

Debiopharmlead

Funding

SEC filings, press & company announcements
  • Undisclosed amountSeries ASep 2022

    Debiopharm (lead)

    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Founder mafia

3 people who came through WhiteLab Genomics went on to found or lead other companies.

Hermine TranieData Scientist/EngineerFounded ClarityCare AIJean-Pascal TraniéBoard MemberFounded DioGenXNicole PaulkScientific Advisory Board MemberFounded Siren Biotechnology

Related companies · 7

Indee LabsIndee Labs develops Hydropore™, a non-viral microfluidic technology for delivering molecules, nucleic acids, proteins, and gene-editing complexes into immune cells for engineered cell therapy research and manufacturing. The platform enables rapid production of high-quality T-cell immunotherapies and other cell therapies with preserved cell function.
IDbyDNAScalable, high throughput DNA sequencing platforms.
Modulari-TModulari-T develops proprietary cell therapy technologies, including the MARC receptor and MoVe platform, based on primary research into immune system architecture. The company serves the cell therapy and immunotherapy market.
Eugit TherapeuticsTissue Targeting Therapies develops therapeutics targeting specific tissues using computational genomics and immunology. The company serves patients through drug development in the biotech/medtech space.
Polaris GenomicsPolaris Genomics is a Veteran-owned biotech startup mapping molecular biomarkers to develop objective, biologically-based diagnostics and novel therapeutics for mental health and neuropsychiatric conditions such as PTSD. It combines genomics and AI to advance precision mental health care.
LEAH LabsLEAH Labs engineers gene-edited CAR-T cell therapies to treat cancer in pet dogs, with the goal of generating translational insights for human cancer therapy. The company uses proprietary gene editing and protein design to develop therapeutic treatments for companion animal oncology.
10x Genomics10x Genomics offers single cell analysis technology, including its Flex assay and Flex Apex product, which use probe-based chemistry and plate-based multiplexing to profile fresh, frozen, and FFPE samples for researchers. The tools support applications in cancer, immunology, and neuroscience, enabling gene expression and multiomic profiling of cell surface protein, intracellular protein, and CRISPR guides.

Companies working in the same space as WhiteLab Genomics.

Legal entities · 2

corporate structure
WhiteLab Genomics Inc.
WhiteLab Genomics, Inc.

In the news

Debiopharm Co-leads a Series A Round in Whitelab Genomics - Debiopharmdebiopharm.com · Sep 2022How WhiteLab Genomics is using AI to aid gene and cell therapy development • TechCrunchtechcrunch.com · Sep 2022

Frequently asked questions

What does WhiteLab Genomics do?
WhiteLab Genomics uses AI and computational methods to analyze biological data and accelerate genomic drug discovery and development. The company serves pharmaceutical and biotech organizations seeking to reduce timelines and de-risk the development of genomic medicines.
Who founded WhiteLab Genomics?
WhiteLab Genomics was founded by David Delbourgo, Julien Cottineau in 2019.
Who are WhiteLab Genomics's investors?
WhiteLab Genomics's investors include Y Combinator, Atlantic Vantage Point, Debiopharm Innovation Fund, Omnes Capital.
Where is WhiteLab Genomics headquartered?
WhiteLab Genomics is headquartered in Paris, FR.